Vaccination Against Typhoid Fever: A Century of Research. End of the Beginning or Beginning of the End?

Chapter

Abstract

As its name implies, typhoid fever is a septicemic illness associated with alteration in consciousness (the Greek word “typhos” means “stupor”). It is cause by the Gram-negative bacillus Salmonella typhi which belongs to the enterobacteriaceae family. In its untreated form, the disease is marked by increasing fever, headache, insomnia, and general malaise. More serious complications include intestinal ­perforations and bleeding, severe alteration in consciousness, and possibly shock, which can be fatal. Similar but usually less severe cases, called paratyphoid fever, are caused by Salmonella paratyphi A, B, and C. Together, S. typhi and S. paratyphi infections are referred to as enteric fevers.

Keywords

Attenuation Polysaccharide Bacillus Diarrhea Trench 

References

  1. 1.
    Louis PCA, Recherches antomiques, pathlogogiques, thérapeutiques, sur la maladie connue sous le nom de gastroentérite, fièvre putride, a dynamique, typhoïde, etc, compareé avec les maladies aiguës les plus ordinaries. Paris: JB Baillière, 1829Google Scholar
  2. 2.
    Bretonneau P. Notice sur la contagion de la dothinentérie. Arch Gen Méd 1829; 21:57Google Scholar
  3. 3.
    Budd W. Typhoid fever: its nature, mode of spreading, and prevention. London: Longmans, 1873Google Scholar
  4. 4.
    Eberth CJ. Organisms present in the organs during abdominal lymphoid infection. Virchows Arch Path Anat 1880; 58:74–81Google Scholar
  5. 5.
    Gaffky G. On the etiology of abdominal typhoid infection. Berlin: Mitteilungen aus dem ­kaiserlichen Gesundheitsamte 1884;2: 372–420Google Scholar
  6. 6.
    Widal GFI, Sicard A. Rescherche de la reaction aggluntinate dans le sang et le sérum desséchés typhiques et dans la sérosité des vésications. Bull Soc Méd Paris (3rd ser) 1896;13:681–682Google Scholar
  7. 7.
    Gröschel DHM, Hornick RB. Who introduced typhoid vaccinations: Almoth Wright or Richard Pfieffer? Rev Infect Dis 1981;6:1251–1254CrossRefGoogle Scholar
  8. 8.
    Wright AE. On the association of serous hemorrhages with conditions of defective blood-coagulopathy. Lancet 1896; 2:807–809CrossRefGoogle Scholar
  9. 9.
    Wright AE, Semple D. Remarks on vaccination against typhoid fever. Br Med J 1897;1:256–259PubMedCrossRefGoogle Scholar
  10. 10.
    Pfieffer R, Kolle W. Experimentelle Untersuchungen zur Frage der Schutzimpfung des Menschen gegen Typhus abdominalis. Disch Med Wochenschr 1896;22:735–737CrossRefGoogle Scholar
  11. 11.
    Friedberger E. Zur Frage der Typhus-intestinalis Choleraschuzimpfung. Z Immunol 1919; 28:119–185Google Scholar
  12. 12.
    Yugoslavia Typhoid Commission. A controlled field trial of the effectiveness of acetone-dried and inactivated and heat-phenol activated typhoid vaccines in Yugoslavia. Bull WHO 1964; 30:623–630Google Scholar
  13. 13.
    Felix A, Pitt RB. A new antigen of Bacillus typhosus. Its relation to virulence and to active and passive immunization. Lancet 1932; ii:186–191Google Scholar
  14. 14.
    Webster ME, Landy M, Freeman ME. Studies on Vi antigen. II. Purification of Vi antigen from Escherichia coli 5396–38. J Immunol 1952; 69:135–142Google Scholar
  15. 15.
    Landy M. Studies on Vi antigens: immunization of human beings with purified Vi antigen. Am J Hyg 1954; 60:52–62PubMedGoogle Scholar
  16. 16.
    Wong WH, Feeley JC. Isolation of Vi antigen and a simple method for its measurement. Appl Microbiol 1972; 24:28–33Google Scholar
  17. 17.
    Tacket CO, Ferriccio C, Robbins J. Safety and immunogenicity of the Salmonella typhi Vi capsular polysaccharide vaccines. J Infect Dis 1986; 154:342–345PubMedCrossRefGoogle Scholar
  18. 18.
    Acharya IL, Lowe CU, Thapa RL. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. N Engl J Med 1987;18:1101–1104CrossRefGoogle Scholar
  19. 19.
    Klugman KP, Gilbertson IT, Koornhof HJ. Protective activity of Vi polysaccharide vaccine against typhoid fever. Lancet 1987; ii: 1165–1169Google Scholar
  20. 20.
    Szu SC, Li X, Schneerson R. Comparative immunigenicities of Vi polysaccharide-protein conjugates composed of cholera toxin or its B subunit as a carrier bound to high- or lower-molecular weight Vi. Infect Immun 1989; 57:3823–3827PubMedGoogle Scholar
  21. 21.
    Germanier R, Furer E. Isolation and characterization of galE mutant Ty21a, of Salmonella typhi: a candidate strain for live oral typhoid vaccine. J Infect Dis 1975; 141:553–558CrossRefGoogle Scholar
  22. 22.
    Levine MM, Taylor DN, Ferriccio C. Typhoid vaccines come to age. Pediat Infect Dis 1989; 8:374–381CrossRefGoogle Scholar
  23. 23.
    Wahdan MH, Serie C, Cerisier Y. A controlled field trial of live Salmonella typhi strain Ty21a oral vaccine against typhoid: three year results. J Infect Dis 1982; 145:292–295PubMedCrossRefGoogle Scholar
  24. 24.
    Levin MM, Ferriccio C, Black RE. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet 1987; i: 1049–1052Google Scholar
  25. 25.
    Levin MM, Ferreccio C, Cryz S, Ortiz E. Comparison of enteric-coated capsules and liquid formulation of Ty21a a typhoid vaccine in a randomized controlled field trial. Lancet 1990; 336:891–894CrossRefGoogle Scholar
  26. 26.
    Ivanoff B, Levine MM, Lambert PH. Vaccination against typhoid fever: present status. Bull WHO 1994; 72:954–971Google Scholar
  27. 27.
    Tacket CO, Hone DM, Losonsky G. Clinical acceptability and immunogenicity of CVD908 Salmonella typhi vaccine strain. Vaccine 1992; 10:443–446PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Unité de Pathogénie Microbienne MoléculaireINSERM U389, Institut PasteurParisFrance

Personalised recommendations